Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2005 Mar 14;92(5):955-60.
doi: 10.1038/sj.bjc.6602395.

Randomised controlled trial of mammographic screening in women from age 40: predicted mortality based on surrogate outcome measures

S Moss  1 , M Waller, T J Anderson, H Cuckle; Trial Management Group
Affiliations
Clinical Trial

Randomised controlled trial of mammographic screening in women from age 40: predicted mortality based on surrogate outcome measures

S Moss et al. Br J Cancer. .

Abstract

A trial in the UK to study the effect on mortality from breast cancer of invitation for annual mammography from the age of 40-41, has randomised a total of 160 921 women in the ratio 1 : 2 to the intervention and control arms. All breast cancers diagnosed in the two arms have been identified, and the histology reviewed. This paper presents the results of an interim analysis using surrogate outcome measures to compare predicted breast cancer mortality in the two arms based on 1287 cases diagnosed to 31.12.1999. Due to earlier diagnosis, there is currently an 8% excess of invasive breast cancers in the intervention arm. The ratio of predicted deaths at 10 years in the intervention arm relative to the control arm, adjusted for this excess diagnosis, ranges from 0.89 (95% confidence interval (CI) 0.78-1.01) to 0.90 (95% CI 0.80-1.01). Screening from age 40 may result in a lower reduction in breast cancer mortality than that observed in other trials including women below age 50. This analysis based on surrogate outcome measures suggests that a reduction in breast cancer mortality may be observed in this trial. However, a number of assumptions have been necessary and firm conclusions must await the analysis of observed mortality from breast cancer.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Flow diagram of the progress through the phases of the trial.
See this image and copyright information in PMC

References

    1. Anderson TJ, Alexander FE, Lamb J, Smith A, Forrest AP (2000) Pathology characteristics that optimize outcome prediction of a breast screening trial. Br J Cancer 83: 487–492 - PMC - PubMed
    1. Anderson TJ, Sufi F, Ellis IO, Sloane JP, Moss S (2002) Implications of pathologist concordance for breast cancer assessments in mammography screening from age 40 years. Hum Pathol 33: 365–371 - PubMed
    1. Bjurstam N, Bjorneld L, Duffy SW, Smith TC, Cahlin E, Eriksson O, Hafstrom LO, Lingaas H, Mattsson J (1997) The Gothenburg Breast Screening Trial. First results on mortality, incidence, and mode of detection for women ages 39–49 years at randomization. Cancer 80: 2091–2099 - PubMed
    1. Blamey RW (1996) The design and clinical use of the Nottingham Prognostic Index in breast cancer. Breast 5: 156–157
    1. Day NE, Duffy SW (1996) Trial design based on surrogate end points - application to comparison of different breast screening frequencies. J R Stat Soc 159: 49–60